Robert E. Waltermire - 14 Jun 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 14 Jun 2024
Net transaction value: -$366,529
SEC form: 4
Accepted by SEC: 18 Jun 2024, 21:39:28 UTC
Prior SEC filing: 14 Jun 2024
Next SEC filing: 17 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jun 2024.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2024, 21:39.

Change

Previous filing in this sequence was filed on 14 Jun 2024.
Current net transaction value: -$366,529.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Options Exercise

Transaction value: $165,471
Shares: +1,900
Change %: +35%
Price: $87.09
Shares after: 7,400
Date: 14 Jun 2024
Ownership: Direct
Footnotes: F1

MDGL transaction

Common Stock

Sale

Transaction value: $532,000
Shares: -1,900
Change %: -26%
Price: $280.00
Shares after: 5,500
Date: 14 Jun 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -1,900
Change %: -16%
Price: $0.000000
Shares after: 10,350
Date: 14 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: $1,900
Exercise price: $87.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.